← Back to screener

TriSalus Life Sciences, Inc. TLSI

Rank #1928 · Nasdaq · $0.2B market cap
Audited by Grant Thornton LLP, no going-concern flag in the latest filing.
Score
38.6
P/E
-7.6
P/B
-8.40
ROE
111.0%
Op. Margin
-122.9%
Debt Ratio
-184%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -7.6x, P/B -8.40x. Ranks in the top 94% of the universe.

Profitability ★★★☆☆
Average

ROE 111.0%. Ranks in the top 47% of the universe.

Safety ★★★★★
Excellent

Debt ratio -184%. Ranks in the top 5% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★★
Excellent

Revenue growth of 59.0% year over year. Ranks in the top 6% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2021–$-0.0B$0.0B$0.0B––
2022–$-0.0B$0.0B$-0.0B–-103
2023$0.0B$-0.0B$-0.0B$-0.1B-293.9-26
2024$0.0B$-0.1B$-0.1B$-0.2B-294.3-29
2025$0.0B$-0.0B$-0.0B$-0.0B-122.9-184

← See the full screener